Education
About Us
Working with TipRanks
Follow Us
Kyowa Kirin Co Ltd (KYKOF)
OTHER OTC:KYKOF
KYKOF Stock Chart & Stats
$16.58
$0.00(0.00%)
At close: 4:00 PM EST
$16.58
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$12.42 - $18.14
Previous CloseN/A
Volume800.00
Average Volume (3M)0.00
Market Cap
$7.70B
Enterprise Value$1.04T
Total Cash (Recent Filing)$218.77B
Total Debt (Recent Filing)$26.13B
Price to Earnings (P/E)19.7
Beta0.19
Next Earnings
May 12, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend Yield2.37%
Share Statistics
EPS (TTM)0.41
Shares Outstanding525,634,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.49
Price to Book (P/B)1.48
Price to Sales (P/S)2.66
P/FCF Ratio22.46
Enterprise Value/Market Cap134.57
Enterprise Value/Revenue2.09
Enterprise Value/Gross Profit2.81
Enterprise Value/Ebitda8.07
Forecast
1Y Price Target
$11.51Price Target Upside-30.56% Downside
Rating ConsensusStrong Sell
Number of Analyst Covering3
EPS Forecast (FY)0.99
Revenue Forecast (FY)$3.27B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Minimal LeverageExtremely low leverage and zero reported debt in 2025 provide durable financial flexibility, lowering solvency risk and preserving optionality for R&D, licensing, or selective M&A. This conservatism supports resilience to reimbursement or product-cycle shocks over the next 2–6 months and beyond.
High Gross Margins And Improving Operating ProfitSustained gross margins near the mid-70s indicate strong product economics and pricing power typical of specialty biologics. Improving operating profitability in 2025 suggests scalable operations and room to fund pipeline investment, making earnings more durable against cost fluctuations.
Consistent Top-line Growth (2020–2025)A multi-year rise in revenue to ~497B demonstrates persistent demand for core therapies and effective commercialization both in Japan and via partners. Steady top-line expansion underpins capacity to reinvest in R&D and supports medium-term scale advantages in specialty markets.
Bears Say
Net Margin VolatilityMaterial swings in net margin reduce predictability of earnings and free cash generation, complicating planning for R&D, dividends, or licensing spends. If driven by mix or one-offs, volatility may persist near-term, weakening confidence in sustainable bottom-line conversion over the next several quarters.
Inconsistent Cash Flow ConversionIrregular conversion of accounting profits into free cash flow makes financing of long-term projects less reliable and increases reliance on working-capital management or partners. This inconsistency raises forecasting risk and constrains the firm’s ability to steadily fund investment or returning capital to shareholders.
Very Low Leverage Constrains Financial EfficiencyWhile conservatism lowers risk, near-zero leverage also caps ROE and capital efficiency versus peers that use targeted debt to amplify returns. Over a 2–6 month horizon this structural choice may limit earnings acceleration or shareholder yield expansion when attractive growth or buyback opportunities arise.
Kyowa Kirin Co News
KYKOF FAQ
What was Kyowa Kirin Co Ltd’s price range in the past 12 months?
Kyowa Kirin Co Ltd lowest stock price was $12.42 and its highest was $18.14 in the past 12 months.
What is Kyowa Kirin Co Ltd’s market cap?
Kyowa Kirin Co Ltd’s market cap is $7.70B.
When is Kyowa Kirin Co Ltd’s upcoming earnings report date?
Kyowa Kirin Co Ltd’s upcoming earnings report date is May 12, 2026 which is in 50 days.
How were Kyowa Kirin Co Ltd’s earnings last quarter?
Kyowa Kirin Co Ltd released its earnings results on Feb 09, 2026. The company reported $0.413 earnings per share for the quarter, beating the consensus estimate of $0.256 by $0.156.
Is Kyowa Kirin Co Ltd overvalued?
According to Wall Street analysts Kyowa Kirin Co Ltd’s price is currently Overvalued.
Does Kyowa Kirin Co Ltd pay dividends?
Kyowa Kirin Co Ltd pays a Semiannually dividend of $0.191 which represents an annual dividend yield of 2.37%. See more information on Kyowa Kirin Co Ltd dividends here
What is Kyowa Kirin Co Ltd’s EPS estimate?
Kyowa Kirin Co Ltd’s EPS estimate is 0.18.
How many shares outstanding does Kyowa Kirin Co Ltd have?
Kyowa Kirin Co Ltd has 525,634,500 shares outstanding.
What happened to Kyowa Kirin Co Ltd’s price movement after its last earnings report?
Kyowa Kirin Co Ltd reported an EPS of $0.413 in its last earnings report, beating expectations of $0.256. Following the earnings report the stock price went up 5.436%.
Which hedge fund is a major shareholder of Kyowa Kirin Co Ltd?
Currently, no hedge funds are holding shares in KYKOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyowa Kirin Co Ltd
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
KYKOF Stock 12 Month Forecast
Average Price Target
$11.51
▼(-30.56% Downside)
Technical Analysis
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Daiichi Sankyo Company
―
Eisai Co
―
ONO Pharmaceutical Co
―
Ownership Overview
―
Insiders
1.86% Mutual Funds
<0.01% Other Institutional Investors
92.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---